microdosing glp-1 perimenopause for Perimenopause: Benefits & Risks Microdosing GLP-1 Medications | Achieve

GLP-1 drugs linked to reduced substance abuse risk in 600k US veterans This title was summarized by AI from the post below

While these findings are encouraging, its important for our patients to understand that robust human clinical trials are still lacking

In brief: CJC-1295 with DAC: Long half-life (~68 days), once or twice weekly dosing, produces GH "bleed" a sustained background elevation rather than a sharp pulse

Technological advancements in peptide synthesis have also made higher-purity versions of these compounds more accessible to independent researchers

Okur MN, Fang EF, Fivenson EM, Tiwari V, Croteau DL, Bohr VA (2020) Cockayne syndrome proteins CSA and CSB maintain mitochondrial homeostasis through NAD(+) signaling

Mechanism + animal data is hypothesis generation, not clinical validation